Systemic Lupus Erythematosus Clinical Trial
Official title:
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Verified date | May 2024 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
Status | Active, not recruiting |
Enrollment | 261 |
Est. completion date | March 31, 2025 |
Est. primary completion date | March 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Completion of SLE Study (NCT03252587) through the protocol-required treatment period, and currently receiving blinded study drug. Note: If a subject is not receiving blinded study drug due to exceptional circumstances (eg, missed investigational product [IP] due to COVID-19 pandemic, delays in study approval, etc), the subject may be allowed to enroll with approval from the BMS Clinical Trial Physician or designee. Exclusion Criteria: - Any disease or medical condition that, in the opinion of the investigator, would make the subject unsuitable for this study, would interfere with the interpretation of subject safety or study results, or considered unsuitable by the investigator for any other reason - Evidence of active tuberculosis (TB) Other protocol-defined inclusion/exclusion criteria apply |
Country | Name | City | State |
---|---|---|---|
Argentina | Local Institution - 0100 | Caba | |
Argentina | Clinica Adventista Belgrano | Ciudad Autonoma de Buenos Aires | Buenos Aires |
Argentina | Local Institution - 0125 | Ciudad Autonoma de Buenos Aires | Buenos Aires |
Argentina | Local Institution - 0122 | Cordoba | |
Argentina | Local Institution - 0095 | Mendoza | |
Argentina | Local Institution - 0098 | Rosario | Santa FE |
Argentina | Local Institution - 0091 | San Miguel De Tucum | Tucuman |
Brazil | Local Institution - 0120 | Curitiba | Parana |
Brazil | Local Institution - 0118 | Goi? | Goias |
Brazil | Local Institution - 0106 | Juiz de Fora | Minas Gerais |
Brazil | Local Institution - 0107 | Porto Alegre | RIO Grande DO SUL |
Brazil | Local Institution - 0116 | Salvador | Bahia |
Brazil | Local Institution - 0111 | Sao Bernardo do Campo | SAO Paulo |
Brazil | Local Institution - 0105 | Sao Paulo | |
Canada | University of Calgary | Calgary | Alberta |
Canada | Local Institution - 0136 | Toronto | Ontario |
Colombia | Local Institution - 0108 | Barranquilla | |
Colombia | Local Institution - 0101 | Bogot | |
Colombia | Local Institution - 0103 | Chia | |
Colombia | Local Institution - 0096 | Zipaquira | |
Hungary | Local Institution - 0039 | Debrecen | |
Hungary | Local Institution - 0038 | Gyula | |
Hungary | Local Institution - 0045 | Szeged | |
Japan | National Hospital Organization Chibahigashi National Hospital | Chiba-shi | Chiba |
Japan | Local Institution - 0065 | Chuo-ku | Tokyo |
Japan | Local Institution - 0092 | Kitakyushu | Fukuoka |
Japan | Hokkaido University Hospital | Sapporo | Hokkaido |
Japan | Local Institution - 0119 | Sapporo-Shi | Hokkaido |
Japan | Local Institution - 0063 | Sendai | Miyagi |
Japan | Local Institution - 0069 | Shimotsuke-city | Tochigi |
Japan | Local Institution - 0066 | Tokyo | |
Japan | Local Institution - 0078 | Tokyo | |
Japan | Local Institution - 0093 | Tokyo | |
Korea, Republic of | Local Institution | Seoul | |
Korea, Republic of | Local Institution - 0053 | Suwon | |
Mexico | Local Institution - 0080 | Leon | Guanajuato |
Mexico | Local Institution - 0086 | Leon | Guanajuato |
Mexico | Local Institution - 0087 | Mexico City | Distrito Federal |
Mexico | Local Institution - 0084 | Monterrey | Nuevo LEON |
Mexico | Local Institution - 0082 | San Luis Potosi | |
Mexico | Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. | Zapopan | Jalisco |
Poland | Local Institution - 0025 | Bydgoszcz | |
Poland | Local Institution - 0015 | Koscian | |
Poland | Local Institution - 0014 | Krakow | |
Poland | Local Institution - 0018 | Krakow | |
Poland | Local Institution - 0027 | Krakow | |
Poland | Local Institution - 0016 | Lublin | |
Poland | Local Institution - 0024 | Poznan | |
Poland | Local Institution - 0029 | Sosnowiec | |
Poland | Local Institution - 0019 | Warsaw | |
Poland | Local Institution - 0022 | Warszawa | |
Poland | Local Institution - 0010 | Wroclaw | |
Poland | Local Institution - 0023 | Wroclaw | |
Romania | Local Institution - 0033 | Brasov | |
Romania | Local Institution - 0004 | Galati | |
Romania | Local Institution - 0002 | Ramnicu Valcea | |
Russian Federation | Local Institution - 0061 | Ekaterinburg | |
Russian Federation | Local Institution - 0056 | Kemerovo | |
Russian Federation | Local Institution - 0072 | Novosibirsk | |
Russian Federation | Local Institution - 0057 | Orenburg | |
Russian Federation | Local Institution - 0062 | Saint - Petersburg | |
Russian Federation | Local Institution - 0070 | Smolensk | |
Russian Federation | Local Institution - 0058 | St. Petersburg | |
Russian Federation | Local Institution - 0055 | Vladimir | |
Russian Federation | Local Institution - 0060 | Yaroslavl | |
Russian Federation | Local Institution - 0068 | Yaroslavl | |
Spain | Local Institution - 0126 | Malaga | |
Spain | Local Institution - 0138 | Sabadell | |
Spain | Local Institution - 0124 | Sevilla | |
Taiwan | Local Institution - 0052 | Taichung | |
Taiwan | Local Institution - 0051 | Taipei | |
Taiwan | Local Institution - 0137 | Taipei | |
Taiwan | Local Institution | Taipei City | |
United States | Local Institution - 0094 | Atlanta | Georgia |
United States | Local Institution - 0041 | Austin | Texas |
United States | Tekton Research - Austin | Austin | Texas |
United States | Local Institution - 0115 | Aventura | Florida |
United States | Local Institution - 0077 | Birmingham | Alabama |
United States | Local Institution - 0044 | Brandon | Florida |
United States | Local Institution - 0123 | Brooklyn | New York |
United States | Local Institution - 0071 | Chapel Hill | North Carolina |
United States | Local Institution - 0121 | Charleston | South Carolina |
United States | Local Institution - 0031 | Charlotte | North Carolina |
United States | Local Institution - 0114 | Dallas | Texas |
United States | Local Institution - 0030 | El Cajon | California |
United States | Local Institution - 0140 | Gainesville | Florida |
United States | Local Institution - 0037 | Houston | Texas |
United States | Local Institution - 0001 | Jackson | Tennessee |
United States | Local Institution - 0050 | Lawrenceville | Georgia |
United States | Local Institution - 0046 | Mesquite | Texas |
United States | Local Institution - 0074 | New Haven | Connecticut |
United States | Local Institution - 0131 | New York | New York |
United States | Local Institution - 0064 | Oklahoma City | Oklahoma |
United States | Local Institution - 0133 | Orlando | Florida |
United States | Local Institution - 0032 | Ormond Beach | Florida |
United States | Local Institution - 0048 | Tampa | Florida |
United States | Local Institution - 0049 | Torrance | California |
United States | Local Institution - 0035 | Wyomissing | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States, Argentina, Brazil, Canada, Colombia, Hungary, Japan, Korea, Republic of, Mexico, Poland, Romania, Russian Federation, Spain, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with Adverse Events (AEs) | Up to 30 days after last treatment dose (approximately 178 weeks) | ||
Primary | Number of participants with Serious Adverse Events (SAEs) | Up to 30 days after last treatment dose (approximately 178 weeks) | ||
Primary | Number of participants with AEs leading to discontinuation | Up to 30 days after last treatment dose (approximately 178 weeks) | ||
Primary | Number of participants with abnormal change from baseline in laboratory measurements over time | Up to 30 days after last treatment dose (approximately 178 weeks) | ||
Primary | Number of participants with abnormal change from baseline in vital signs over time | Up to 30 days after last treatment dose (approximately 178 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03843125 -
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
Recruiting |
NCT05698173 -
Systemic Lupus Erythematosus and Accelerated Aging
|
N/A | |
Active, not recruiting |
NCT01649765 -
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
|
Phase 2 | |
Recruiting |
NCT05704153 -
Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)
|
N/A | |
Completed |
NCT05048238 -
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
|
Phase 1 | |
Recruiting |
NCT06056778 -
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
|
||
Completed |
NCT04358302 -
Individual Patient Exposure and Response in Pediatric Lupus
|
N/A | |
Completed |
NCT03802578 -
The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients
|
N/A | |
Completed |
NCT02554019 -
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT04835883 -
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
|
Phase 2 | |
Terminated |
NCT02665364 -
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00278538 -
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT03252587 -
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT02066311 -
Nelfinavir in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT01892748 -
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
|
N/A | |
Terminated |
NCT01689025 -
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
Unknown status |
NCT01712529 -
Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients
|
N/A | |
Completed |
NCT00962832 -
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
|
Phase 2 |